Taken together, our results suggest that HAT inhibits the development of erlotinib resistance in PC9 cells by attenuating HGF production from ECs, highlighting the multifaceted action of HAT on the complex crosstalk between ECs and cancer cells (Figure 7). This evidence concerns the gene TMPRSS11D and cancer.